Home
Contact us
Site map
Québec.ca
FAQ
Français
Advanced search
Consolidated Statutes and Regulations
Consolidated Statutes
Consolidated Regulations
Annual Statutes and Regulations
Annual Statutes
Annual Regulations
Additional information
Québec Official Publisher
What’s new?
Information note
Policy of the Minister of Justice
Laws: Amendments
Laws: Provisions not in force
Laws: Provisions brought into force
Annual Statutes: PDF versions since 1996
Regulations: Amendments
Annual Regulations: PDF versions since 1996
Court Decisions
P-12, r. 6
- Regulation respecting the medications that a podiatrist who obtained a permit to practise before 1976 may administer or prescribe
Table of contents
Enabling statute
1
Alphanumeric
Title
P-12
Podiatry Act
Occurrences
0
Full text
Updated to 1 June 2024
This document has official status.
chapter
P-12, r. 6
Regulation respecting the medications that a podiatrist who obtained a permit to practise before 1976 may administer or prescribe
PODIATRISTS — MEDICATIONS
Podiatry Act
(chapter P-12, s. 12)
.
P-12
09
September
01
1
2012
O.C. 1057-91
;
O.C. 173-2020, s. 1
.
1
.
A podiatrist who obtained a permit to practise before 1 January 1976 may, in the practice of the profession, administer or prescribe the medications listed in Schedule I.
O.C. 1057-91, s. 1
;
O.C. 142-2003, s. 1
;
173-2020
O.C. 173-2020
,
s.
2
1
.
2
.
Until 1 May 2021, a podiatrist to who section 1 does not apply, who obtained a permit to practise before 1 May 2020 and who has not yet undergone the training provided for in the Regulation respecting the medications that a podiatrist may administer or prescribe (
chapter P-12, r. 6.1
) may, in the practice of the profession, administer or prescribe the medications listed in Schedules I and II.
O.C. 1057-91, s. 2
;
O.C. 142-2003, s. 2
;
173-2020
O.C. 173-2020
,
s.
2
1
.
3
.
(Omitted).
O.C. 1057-91, s. 3
.
SCHEDULE I
(
ss. 1 and 2
)
1.
Any medication listed below, subject to the restrictions indicated:
Medications
Restrictions
Aluminium and its salts
Amcinonide
Anthralin
Silver sulfadiazine
Bacitracin and its salts
Beclomethasone and its salts
Benzalkonium
Benzocaine
Betamethasone dipropionate
Betamethasone valerate
Bupivacaine and its salts
Pharmaceutical form intended for administration by injection for local use only
Calcipotriol
Calcitriol
Camphor
Cantharidin
Cetirizine hydrochloride
Chlorhexidine and its salts
Ciclopirox olamine
Cinchocaine (dibucaine)
Clioquinol
Clobetasol proprionate
Clotrimazole
Cyproheptadine hydrochloride
Desonide
Desoximetasone
Diphenhydramine
Pharmaceutical form intended for oral and topical administration
Efinaconazole
Epinephrine (adrenaline)
Erythromycin
Powder extemporaneous mixture or topical preparation
Ethyl chloride
Fluocinolone acetonide
Fluocinode
Formalin
Framycetin sulfate
Fusidic acid
Gentamicin sulfate
Mineral tar
Vegetal tar
Gramicidin
Hexachlorophene
Hydrocortisone and its salts
Pharmaceutical form intended for topical administration
Hydroxyzine hydrochloride
Pharmaceutical form intended for oral administration
Povidone iodine
Ketoconazole
Pharmaceutical form intended for topical administration
Lactic acid
Lidocaine and its salts
Pharmaceutical form intended for administration by injection for local use only
Loratadine
Pharmaceutical form intended for oral administration
Lorazepam
Pharmaceutical form intended for oral and sublingual administration
Quantity limited to 4 tablets
Mepivacaine
Pharmaceutical form intended for administration by injection for local use only
Methylpolysiloxanes (dimethicone)
Methylprednisolone acetate
Miconazole nitrate
Mometasone furorate
Mupirocin
Neomycin sulfate
Nystatin, its salts and derivatives
Pharmaceutical form intended for topical administration
Dressings and products associated with the treatment of wounds and alterations of the skin and teguments
Phenol
Podophyllin
Polymyxin B sulfate
Pramoxine
Promethazine hydrochloride
Resorcinol and its salts
Triethanolamine salicylate
Salicylic acid
Silicone (dimethicone)
Sulphur colloidal
Sulphur precipitate
Sulphur sublimate
Tazarotene
Tolnaftate
Triamcinolone acetonide
Pharmaceutical form intended for topical administration
Trichloroacetic acid
Trimeprazine tartrate
Urea
Pharmaceutical form intended for topical administration, with a concentration of 40% or less
2.
Any other medication intended for topical or oral administration that is not listed in Schedule I of the Regulation respecting the terms and conditions for the sale of medications (
chapter P-10, r. 12
).
3.
Any combination of medications of this Schedule, subject to the applicable restrictions.
O.C. 1057-91, Sch. I
;
O.C. 142-2003, s. 3
;
O.C. 522-2005, s. 1
;
173-2020
O.C. 173-2020
,
s.
3
1
.
SCHEDULE II
NOTE: Medications without specification are intended for topical application.
________________________________________________________________
Substances Specification
________________________________________________________________
Acetaminophen Pharmaceutical form intended
for oral and rectal administration
Acetaminophen and Pharmaceutical form intended
codeine for oral administration
(in combination) containing 30 mg or less of
codeine per tablet
Acetic, Quantity limited to 24 tablets/
glacial acid 72 hours
Acetylsalicyclic Pharmaceutical form intended
acid for oral administration
Aluminium and its salts
Almond, sweet oil
Amcinonide Quantity limited for 30 days
Anthralin (dithranol)
Silver nitrate
Silver sulfadiazine
Colloidal oatmeal
Bacitracin and its salts
Beclomethasone and its salts
Benzalkonium
Benzocaine
Betamethasone Pharmaceutical forms
acetate and intended for administration by
phosphate intramuscular or intradermal
injection
Betamethasone benzoate
Betamethasone Quantity limited for 30 days
dipropionate
Betamethasone valerate
Bleomycin sulfate Pharmaceutical form injectable in
the plantar lesion without
exceeding 0.8 units up to a maximum
of 5 units per treatment
Bupivacaine and Pharmaceutical form intended for
its salts administration by injection for
local use only
Calcipotriol
Camphor
Cantharidin
Capsaicin
Celecoxib Pharmaceutical form intended for
oral administration
Quantity limited for 30 days
Cetirizine Pharmaceutical form intended for
hydrochloride oral administration
Chlorhexidine and its salts
Chlorprocaine Pharmaceutical form intended for
hydrochloride administration by injection for
local use only
Ciclopirox olamine
Cinchocaine
Clioquinor
(iodochlorhydroxyquin)
Clobetasol Quantity limited for 30 days
proprionate
Clobetasone butyrate
Clotrimazole
Dakin’s solution
Desonide
Desoximetasone Quantity limited for 30 days
Dichloracetic acid
Diclofenac, Pharmaceutical form intended
potassic and sodic for oral administration
Quantity limited for 30 days
Diflucortolone Quantity limited for 30 days
valerate
Dyphenhydramine Pharmaceutical forms intended
for oral administration and
administration by intramuscular,
subcutaneous or intradermal
injection
Epinephrine Pharmaceutical forms for the
(adrenaline) emergency treatment of
anaphylactic reactions in the
form of auto-injector or vial
Pharmaceutical form associated
with local anaesthetics
Erythromycin
Ethyl chloride
Fluocinolone Quantity limited for 30 days
acetonide
Fluocinode Quantity limited for 30 days
5-fluorouracil 5% pharmaceutical form intended
for topical application in the
case of plantar warts resistant to
first-line treatments
Formaline
Framycetin sulfate
Fusidic acid
Gentamicin sulfate
Gentian, violet
Mineral and vegetal tar
Gramicidin
Hexachlorophene
Mineral oil
Hydrocortisone and its salts
Hydroxyzine Pharmaceutical form intended for
hydrochloride oral administration
Ibuprofen Pharmaceutical form intended for
oral administration
Quantity limited for 30 days
Povidone iodine
Ketoconazole
Lactic acid
Lanolin
Lidocaine and Pharmaceutical forms intended for
its salts topical application and
administration by injection for
local use only
Loratadine Pharmaceutical form intended for
oral administration
Lorazepam Pharmaceutical form intended for
oral and sublingual administration
in anticipation of surgical
procedures, containing 0.5 mg or
1 mg of Lorazepam per tablet
Quantity limited to 4 tablets
Menthol
Mepivacaine Pharmaceutical form intended for
administration by injection
for local use only
Methylpolysiloxanes
Methylprednisolone Pharmaceutical forms intended for
acetate topical application and
administration by injection for
local use only
Miconazole nitrate
Mometasone furorate
Mupirocin
Naproxen Pharmaceutical form intended for
oral administration
Quantity limited for 30 days
Neomycin sulfate
Nystatin
Phenol
Podophyllin
Polymyxin B sulfate
Pramoxine
Prilocaine Pharmaceutical forms intended for
topical application and
administration by injection for
local use only
Procaine Pharmaceutical form intended for
administration by injection for
local use only
Resorcinol and its salts
Methyl salicylate
Triethanolamine salicylate
Salicylic acid
Silicone
Sulphur, colloidal,
precipitate or sublimate
Tazarotene
Terbinafine
Tetracaine and Pharmaceutical forms intended for
its salts topical application and
administration by injection for
local use only
Tolnaftate
Triamcinolone Quantity limited for 30 days
acetonide
Triamcinolone Pharmaceutical forms intended for
hexacetonide administration by intramuscular or
intradermal injection
Quantity limited for 30 days
Trichloroacetic acid
Urea Pharmaceutical form intended for
topical application, with a
concentration of 30% or less
White petroleum jelly
Zinc oxide
O.C. 142-2003, s. 3
;
O.C. 522-2005, s. 2
;
173-2020
O.C. 173-2020
,
s.
4
1
1
.
REFERENCES
O.C. 1057-91, 1991 G.O. 2, 3231
O.C. 142-2003, 2003 G.O. 2, 1013
O.C. 522-2005, 2005 G.O. 2, 1872
173-2020, 2020 G.O. 2, 776
O.C. 173-2020, 2020 G.O. 2, 776
Copy
Select this element
Select parent element
Unselect all
Copy to Drafting
Copy to LAW
Copy to Clipboard
×
To copy : Ctrl+C
0
Contact us
Site map
Québec.ca
Accessibility
Privacy policy
© Gouvernement du Québec
Selections
×
Show
Selections in current document
All selections in the collection
Selected elements
Delete all selections
Show selections
Cyberlex
×
Version 2.2.0.3